GlassScriptPhysician profile
Ron Douglas Schafer
NPI 1497806038
$3,850.84
in general payments reported to CMS, 2019-2025
31 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $421 · 2022: $618 · 2023: $526 · 2024: $1,675 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,234 · Travel and Lodging: $555 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,234.12 |
| Travel and Lodging | $554.78 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,077.97 | 2021-2025 | Nushield, Affinity, Puraply Wound Matrix |
| Mimedx Group, INC. | $413.88 | 2024 | |
| Pfizer INC. | $350.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $345.06 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $209.03 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $191.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $159.11 | 2021-2024 | Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $156.13 | 2021-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.13 | 2021-2025 | Jardiance, Stiolto Respimat |
| Mylan Specialty L.P. | $104.97 | 2021-2023 | Yupelri |
| Abbvie INC. | $78.60 | 2021-2024 | |
| Kerecis Limited | $64.77 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Merck Sharp & Dohme LLC | $64.45 | 2021-2024 | Gardasil 9, Gardasil, Vaxelis |
| Verona Pharma, INC. | $63.92 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $55.48 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $48.83 | 2021-2022 | |
| Amarin Pharma, INC. | $44.72 | 2021-2022 | |
| Glaxosmithkline, LLC. | $39.88 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Radius Health, INC. | $32.74 | 2021-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $30.45 | 2022 | |
| Viatris Specialty LLC | $27.97 | 2025 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $27.18 | 2021 | |
| Janssen Pharmaceuticals, INC | $24.94 | 2021-2022 | |
| Abiomed | $20.42 | 2025 | |
| Acadia Pharmaceuticals INC | $17.55 | 2023 | Nuplazid |
| Axsome Therapeutics, INC. | $16.43 | 2023 | Auvelity |
| Lundbeck LLC | $16.39 | 2024 | Rexulti |
| Xeris Pharmaceuticals, INC. | $14.36 | 2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $14.11 | 2021 | |
| Itamar Medical INC | $14.09 | 2025 | Watchpatone |
| Dexcom, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Schafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.